Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/11/2008
 
First Published:
7/26/2003
1.
Phase I/II Study of GTI-2040 and Capecitabine in Patients With Advanced or Metastatic Renal Cell Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
LORUS-L01-1409
NCT00056173
Last Modified:
10/2/2006
 
First Published:
11/20/2003
2.
Phase II Study of GTI-2040 and Docetaxel in Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors (Phase I study closed to accrual as of 8/5/2004)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI
PMH-PHL-017
NCI-6104, NCT00074022, 6104
Last Modified:
8/8/2007
 
First Published:
8/24/2003
3.
Phase II Study of GTI-2040 and Capecitabine in Patients With Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CCC-PHII-46
UCD-200311533-1, CHNMC-PHII-46, NCI-6093, NCT00068588, 6093
Last Modified:
7/16/2007
 
First Published:
6/23/2004
4.
Phase II Study of GTI-2040, Docetaxel, and Prednisone in Patients With Hormone-Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
PMH-PHL-024
NCI-6102, 6102, NCT00087165
Last Modified:
6/14/2007
 
First Published:
9/24/2003
5.
Phase I Study of GTI-2040 and High-Dose Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
OSU-0304
OSU-20030030, NCI-6108, NCT00070551, 6108
Last Modified:
11/21/2007
 
First Published:
2/20/2004
6.
Phase I Study of GTI-2040 and Gemcitabine in Patients With Metastatic or Unresectable Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
CTRC-IDD-0306
NCI-6090, NCT00078962, 6090
Last Modified:
3/28/2006
 
First Published:
5/28/2004
7.
Phase I Study of GTI-2040, Oxaliplatin, and Capecitabine in Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
CCC-PHI-41
CHNMC-PHI-41, NCI-6099, 6099, NCT00084643
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute